- Celgene Corporation stock price today and history
Celgene Corporation (CELG) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Celgene Corporation stock price, CELG
Celgene Corporation stock chart:
Celgene Corporation close price: 119.32
Stock price forecast:
UP TO +0.08%
Total forecasts: 81
Reached: 60 (74.07%)
Total Win: 190.82 (153.55%)
Showing 1-10 of 430 items.
|Date of Forecast||Stock Price||Target Price||Forecast Reached Date|
Celgene Corporation latest news:
AbbVie, Celgene and 2 More Major Biotechs Reporting Earnings Thursday
OncoMed Pharma stock drops 45% after midstage clinical trial miss; Bayer opting not to license two drugs
OncoMed Pharmaceuticals Inc. shares dropped 44.6% in premarket trade Monday after news that the company's midstage pancreatic cancer trial had missed its primary endpoint and that Bayer AG ADR would not be using its option to license two of OncoMed's cancer drugs. OncoMed said that its demcizumab, part of a partnership with Celgene Corp. , was being tested with two chemotherapy drugs in previously untreated metastatic pancreatic cancer. The company said it will be discontinuing the clinical trial after Monday's results. OncoMed said it will also discontinue enrollment in other ongoing trials for demcizumab and examine the data. OncoMed also said Monday that Bayer would not be licensing two other drugs, vantictumab and ipafricept, "for strategic reasons," and that OncoMed will keep the global development and commercialization rights to both drugs starting in June. OncoMed said it has fully funded development of both drugs -- which are phase 2-ready, it said -- with the more than $90 million it got from the partnership. OncoMed was eligible for up to $387.5 million per program, or $775 million for both drugs, according to its website. OncoMed shares were valued at $8.76 as of Friday's close. Shares have risen 0.1% over the last three months, compared with a 3.8% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Juno Therapeutics stock declines 4% after decision to not move forward with cancer drug
Juno Therapeutics Inc. stock declined as much as 4% after the bell on Wednesday after the company said it won't be moving forward with its JCAR015 drug, which is intended for relapsed or refractory acute lymphoblastic leukemia, saying it recognizes the "unfortunate and unexpected toxicity" of the drug. The company also reported fourth-quarter earnings. Several patients died during clinical trials last year in the summer and then the fall. The company initially attributed the deaths to the chemotherapy drug used with JCAR015, which it removed from the trial, but then two additional patients died, the company said in late November. The company said its investigation found that certain patient, product and other characteristics may have added to the trial's risk. Changes could allow the trial to proceed, Juno said, but it would require another phase 1 trial. As such, Juno said it, along with partner Celgene Corp. , made the "strategic decision" to focus resources on another drug in this disease area, with a trial planned for next year. Juno shares have increased 27.2% over the last three months, compared with a 9.4% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Celldex Therapeutics, Inc.CLDX
Cellectar Biosciences, Inc.CLRB
Cellectar Biosciences, Inc.CLRBW
Cellular Biomedicine Group, Inc.CBMG
Celsus Therapeutics PlcCLTX